Eucrisa (crisaborole) / Pfizer - LARVOL DELTA

Drug development in dermatology: challenges in treating young patients. (PubMed, Expert Opin Pharmacother) - "For crisaborole for atopic dermatitis, the FDA accepted pivotal trials involving patients 2-79 years; the EMA accepted this as part of its PIP...Companies must possess a deep understanding of the clinical landscape, considerable patience, and sometimes seek external experts' support. A gap has become wider between US and EU, with the EU increasingly falling behind in drug development."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics • Psoriasis

Study on the microscopic characteristics of skin blood vessels in inflammatory skin diseases and the efficacy and safety of abrocitinib tablets combined with Crisborole ointment in the treatment of moderate to severe atopic dermatitis (ChiCTR) - P=N/A | N=300 | Completed | Sponsor: China-Japan Friendship Hospital; The Beijing Qingnang Huimin Medical Research Institute Co., Ltd.

New trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Pfizer introduces two novel therapies to treat patients across the atopic dermatitis disease spectrum (The Star) - "PFIZER, a global biopharmaceutical company, today announced the availability of Cibinqo (abrocitinib) and Staquis (crisaborole) as new additions to the atopic dermatitis treatment spectrum in Malaysia. Cibinqo is a once-daily oral pill indicated for the treatment of patients 12 years of age and older with moderate-to-severe atopic dermatitis..."

Launch non-US • Atopic Dermatitis

PAD: Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (clinicaltrials.gov) - P4 | N=72 | Terminated | Sponsor: Boston University | N=118 ➔ 72

Enrollment change • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Molecular mechanism of crisaborole combined with erythromycin against methicillin-resistant Staphylococcus aureus in vivo and in vitro. (PubMed, Front Microbiol) - "Here, we identified (AN2728) produced a significant synergistic bactericidal effect with erythromycin, cefuroxime and rifampicin against different bacterial strains of Staphylococcus aureus (S. Moreover, in a mouse skin infection model of MRSA, the combination of AN2728 and erythromycin showed remarkable treatment benefits, as shown by significantly reduced bacterial loading (p < 0.05), pathological lesions of the skin and an obvious anti-inflammatory effect (p < 0.05). To our knowledge, this study is the first to establish that AN2728 can cooperate with antibiotics such as erythromycin to completely kill MRSA and that AN2728 can be used to extend the usage life of different antibiotics to address the inevitability of severe MRSA infection."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease

Rural-urban disparities in the use of FDA-approved steroid-sparing topical medications for inflammatory dermatologic conditions: A DataDerm study (AAD 2025) - " Compared to rural patients, urban patients were more likely to be prescribed 3 of 6 topicals queried: crisaborole (OR 1.46, p<0.001), roflumilast (OR 11603130, p<0.001), and tacrolimus (OR 1.57, p<0.001). While odds ratios for pimecrolimus, tapinarof, and tazarotene also exceeded 1.0, no statistically significant differences were observed for these medications. There is an evident disparity in prescribing patterns for steroid-sparing topical medications between urban and rural populations, with the former being less likely to incur steroid-related adverse effects such as dermal atrophy. This could be attributable to differences in the concentration of dermatologists between these areas (4), with rural patients encountering significantly more obstacles in accessing dermatologic care."

Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Psoriasis

Comparative evaluation of the efficacy and safety of crisaborole ointment versus tacrolimus ointment for the topical treatment of atopic dermatitis-A randomized controlled trial (AAD 2025) - "Localized burning sensation was seen in both groups, with tacrolimus showing more incidence of the adverse event. Conclusion The study demonstrated that crisaborole and tacrolimus ointment have comparable efficacy in treating atopic dermatitis; however, crisaborole has a superior safety profile."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Pooled Safety and Local Tolerability of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials of Patients With Atopic Dermatitis: Subgroup Analysis of Patients With Prior Inadequate Response, Intolerance, and/or Contraindications to Topical Treatments (AAD 2025) - P3 | "Roflumilast cream 0.15% was well tolerated in patients with AD, including those with prior TCS, TCI, and/or crisaborole failure. Sponsored by Arcutis Biotherapeutics, Inc."

Clinical • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pain

Tapinarof cream (Vtama) for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Atopic dermatitis: a comprehensive updated review of this intriguing disease with futuristic insights. (PubMed, Inflammopharmacology) - "The FDA has approved targeted and well-tolerated immunomodulators including biologics like dupilumab and crisaborole, and small molecules such as baricitinib, as novel therapies for AD. Finally, the new implication of artificial intelligence (AI) in AD management is explored, where AI can speed up diagnosis and therapy. The PubMed, Google Scholar, and ScienceDirect databases were used for this review."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Successful treatment of generalized inflammatory linear verrucous epidermal nevus with a somatic mutation in KRT10 with crisaborole 2% ointment. (PubMed, Clin Exp Dermatol) - "An excellent response was achieved after application of crisaborole 2% ointment. Our data reveal the crucial role of activation of immune response in the development of ILVEN with somatic KRT10 mutations, and suggest crisaborole 2% ointment should be considered for the treatment of ILVEN."

Journal • Dermatology • Rare Diseases • IFNG • IL12A • IL17A • IL23A • KRT10

Eucrisa for Atopic Dermatitis (clinicaltrials.gov) - P1 | N=28 | Active, not recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Jul 2025 ➔ Oct 2025 | Trial primary completion date: Jan 2025 ➔ May 2025

Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study. (PubMed, Paediatr Drugs) - P=N/A | "Proactive treatment with crisaborole ointment for children older than 2 years with mild-to-moderate AD effectively reduces flare-ups and reliance on topical corticosteroids, demonstrating good tolerability and safety."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Evaluating Efficacy and Safety of Crisaborole in Managing Childhood Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-Analysis. (PubMed, Br J Hosp Med (Lond)) - "Conclusion Crisaborole demonstrates substantial efficacy in treating mild to moderate AD compared to vehicle therapies, as it reduces the signs and symptoms of the disease. Furthermore, crisaborole is well tolerated and has an acceptable safety profile in treating mild to moderate AD patients."

Clinical • Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pediatrics • Pruritus

Characterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by Oxazolone. (PubMed, Exp Dermatol) - "Atopic dermatitis (AD) is a common inflammatory skin disorder characterised by hypersensitivity to allergens, eczematous lesions and pruritus. Oral (cyclosporine, prednisolone and baricitinib) and topical treatments (betamethasone, tacrolimus and crisaborole) were effective inhibiting the induced pathology, as well as modulating the cytokine gene signature of AD. In conclusion, our 4 oxazolone challenges model recapitulates many of the key features of the disease and is responsive to AD standard of care therapies in humans."

Journal • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus • Psoriasis • IL13 • IL4

An evaluation of the recently approved drugs for treating atopic dermatitis in the context of their safety and efficacy: a systematic review and meta-analysis. (PubMed, Expert Rev Clin Immunol) - "The three studied topical AD treatments were found to be significantly effective compared to control groups (crisaborole, OR = 1.78, 95% CI [1.51-2.10], delgocitinib, OR = 6.34, 95% CI [3.57-11.27], and ruxolitinib, OR = 7.30, 95% CI [5.10-10.44]). Delgocitinib and ruxolitinib demonstrated favorable safety and effectiveness profiles across various age cohorts, whereas crisaborole raised concerns over its safety and efficacy, particularly in children."

Journal • Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Supramolecular Deferoxamine-Crisaborole Nanoparticle Targets Ferroptosis, Inflammation, and Oxidative Stress in the Treatment of Retinal Ischemia/Reperfusion Injury. (PubMed, Nano Lett) - "Electroretinogram and histochemical analysis confirm the nanoparticles' superior protective effects compared to control treatments. This study proposes a novel nanoparticle approach for retinal IR injury by simultaneously targeting multiple pathogenic pathways."

Journal • Cardiovascular • Inflammation • Oncology • Reperfusion Injury • ACSL4 • GPX4 • HMOX1 • IL1B • IL6 • TNFA

Atypical necrobiosis lipoidica of the face and scalp successfully treated with combined baricitinib and crisaborole. (PubMed, J Dermatol) - No abstract available

Journal • Metabolic Disorders

Crisaborole 2% ointment as an effective and safe option in mild to moderate atopic dermatitis: data from a pilot study. (PubMed, Clin Exp Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Updated consensus guidelines for management of moderate-to-severe atopic dermatitis in Singapore: Integrating biologics, Janus kinase inhibitors and conventional therapies. (PubMed, Ann Acad Med Singap) - "Since 2016, several therapies have been approved for treating atopic dermatitis (AD) in Singapore, including biologics, oral Janus kinase (JAK) inhibitors and topical crisaborole...Key updates are the inclusion of dupilumab and JAK inhibitors as potential first-line treatments for moderate-to-severe AD, in certain populations...The consensus statements developed are intended to supplement the 2016 Singapore treatment guidelines for AD. Further revisions may be required when new evidence and/or treatments become available."

Clinical guideline • Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Comparative evaluation of the efficacy and safety of crisaborole ointment (2%) versus tacrolimus ointment (0.1%) for the topical treatment of atopic dermatitis: an open-labeled single-blinded randomized controlled trial. (PubMed, Int J Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Chemical, biochemical, and structural similarities and differences of dermatological cAMP phosphodiesterase-IV inhibitors. (PubMed, J Invest Dermatol) - "Roflumilast, the third phosphodiesterase-IV (PDE4) inhibitor approved for use in dermatology, is indicated for topical treatment of psoriasis, seborrheic dermatitis, and atopic dermatitis, whereas its two predecessors, apremilast and crisaborole, are indicated for oral treatment of psoriasis and topical treatment of atopic dermatitis, respectively. These residues bind one Zn and one Mg ions plus five structural water molecules for orienting an attacking μ-hydroxyl/μ-oxo anion and for stabilizing two non-bridging phosphate oxygen atoms. The arrangement of the two divalent metal ions in PDEs is not related to that of the classic mechanism for general phosphoryl transfer."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • Seborrheic Dermatitis

NAME THAT RASH: COULD IT BE TERRA FIRMA-FORME DERMATOSIS? (ACAAI 2024) - "She uses scented creams, CeraVe emollient, Dove soap, triamcinolone, Eucrisa, fabric softener, and bath bombs...An example of Terra Firma-Forme Dermatosis on neck of a 15-year-old girl. "Diagnostic Sign of Terra Firma-Forme Dermatosis" written by Faiza M. Saleh Al Ali, Waqas S. Abdulwahhab, Fatima A. Qaderi, published by Journal of Cosmetics, Dermatological Sciences and Applications, Vol.10 No.3, 2020 104 Abstracts: Medically Challenging Case Abstracts / Ann Allergy Asthma Immunol 00 (2024) 1−110"

Aesthetic Medicine • Allergic Rhinitis • Asthma • Atopic Dermatitis • Conjunctivitis • Dermatology • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Respiratory Diseases • Urticaria

Sustained Improvement in Atopic Dermatitis Disease Control and Treatment Satisfaction with Dupilumab in Clinical Practice: 5-Year Follow-up Results From the RELIEVE-AD Study (EADV 2024) - "The outcomes presented here are disease control, assessed using the Atopic Dermatitis Control Tool (ADCT; range: 0 – 24; total score 80%) with moderate-to-severe AD treated with dupilumab reported controlled disease and remained satisfied with their treatments at 5 years in real-world clinical practice. The majority of dupilumab-treated patients did not use concomitant AD medications at year 5."

Clinical • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Respiratory Diseases

Lichen Planus Pigmentosus Successfully Treated with Roflumilast Cream 0.3% (EADV 2024) - "Treatments for lichen planus pigmentosus include topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, tranexamic acid and isotretinoin1...Roflumilast is more potent than apremilast and crisaborole, with roflumilast more closely mimicking the three key binding sites of cAMP to PDE43,4...Prior treatments, including clobetasol, were ineffective... This case report of a 36-year-old male with lichen planus pigmentosus refractory to topical corticosteroids and tacrolimus ointment was successfully treated with topical roflumilast 0.3% cream once daily resulting in resolution of pruritus and normalization of skin pigmentation. These results suggest that roflumilast cream 0.3% can be a safe and well tolerated treatment option for patients with lichen planus pigmentosus who warrant the needed for alternative treatments. Further clinical evaluation is necessary to evaluate topical roflumilast cream 0.3% as a potential treatment option for lichen planus..."

Dermatitis • Dermatology • Dermatopathology • Immunology • Infectious Disease • Lichen Planus • Pruritus • Psoriasis • Seborrheic Dermatitis • CD4 • CD8